Please login to the form below

Not currently logged in
Email:
Password:

Vyvanse

This page shows the latest Vyvanse news and features for those working in and with pharma, biotech and healthcare.

Shire separates out neuroscience as it considers its future

Shire separates out neuroscience as it considers its future

The company’s new neuroscience division will look to build on its ADHD heritage and newer products like Intuniv, Vyvanse and Mydayis, the latter of which was recently launched in the

Latest news

  • Shire claims FDA approval for slow-cooked ADHD drug Shire claims FDA approval for slow-cooked ADHD drug

    top ADHD seller Vyvanse (lisdexamfetamine dimesylate) - which pulled in $2bn in sales last year, a rise of 17% and added another $563m in the first quarter. ... Vyvanse remains under patent challenge from would-be generic rivals, but so far Shire has

  • Shire pitching at adult ADHD product launch in 2017 Shire pitching at adult ADHD product launch in 2017

    Breaking into the adult ADHD - as well as a sideways move into binge-eating disorder with paediatric ADHD therapy Vyvanse (lisdexamfetamine) - could eventually double sales of Shire's psychiatric portfolio by

  • Monica Seles to front Shire’s binge eating disorder campaign Monica Seles to front Shire’s binge eating disorder campaign

    Shire recently won the first approval in the US for a medicine to help people with binge eating disorder with FDA backing for Vyvanse (lisdexamfetamine dimesylate). ... Vyvanse's efficacy in the treatment of binge eating was shown in two clinical trials

  • Shire gets FDA nod for first binge-eating treatment Shire gets FDA nod for first binge-eating treatment

    Vyvanse already available as ADHD treatment. Shire's big-selling Vyvanse brand has become the first drug approved in the US to help people with binge-eating disorder. ... The approval of Vyvanse provides physicians and patients with an effective option

  • Shire reaches $56.5m US marketing malpractice settlement Shire reaches $56.5m US marketing malpractice settlement

    The allegations included its attention deficit disorder (ADHD) drugs Adderall XR and Vyvanse. ... Vyvanse sales amounted to $359.5m, 25% of the company's total revenue during the period.

More from news
Approximately 3 fully matching, plus 39 partially matching documents found.

Latest Intelligence

  • Challenging perceptions Challenging perceptions

    However, with attention deficit hyperactivity disease (ADHD) treatment Vyvanse accounting for more than a quarter of its revenues it's clear that, even after its combination with Baxalta is completed, neuroscience ... Meanwhile, the US also has the

  • Pharma deals during June 2014 Pharma deals during June 2014

    study with Vyvanse.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Branding Science

We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...

Latest intelligence

Report: Customer experience, shaping digital healthcare
In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Biomarker
Encouraging signs in biomarker R&D
The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...

Infographics